ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: TH-PO059

SGLT2 Inhibitor Dapagliflozin Reduces Biomarkers of Tubular Injury in Patients with Acute Heart Failure

Session Information

Category: Acute Kidney Injury

  • 102 AKI: Clinical, Outcomes, and Trials


  • Wattanakul, Jananya, Bhumibol Adulyadej Hospital, Bangkok, Bangkok, Thailand
  • Gojaseni, Pongsathorn, Bhumibol Adulyadej Hospital, Bangkok, Bangkok, Thailand
  • Chittinandana, Anutra, Bhumibol Adulyadej Hospital, Bangkok, Bangkok, Thailand

Sodium-glucose co-transporter 2 (SGLT2) inhibitors improve renal and cardiovascular outcomes in heart failure patients, and there is growing evidence that it would decrease the risk of acute kidney injury (AKI). The aim of this study was to assess the effect of SGLT2 inhibitor on biomarkers of tubular injury in patients with acute heart failure (AHF).


Patients who hospitalized for AHF were randomized to dapagliflozin added to standard therapy or control group for 28 days. The primary outcome was the change of urinary [TIMP-2] x [IGFBP7] by NephroCheck® from baseline. The secondary outcome was incidence of AKI, the change of serum creatinine from baseline, adverse events and 28-day mortality.


A total of 32 patients underwent randomization. Compared with control group, dapagliflozin group significantly reduced urinary [TIMP-2] x [IGFBP7] after 7 days [dapagliflozin: -0.03 ± 0.37 (ng/mL)2/1000; control: +0.4 ± 0.50 (ng/mL)2/1000; P = 0.022] and continue this trend until the end of the study [dapagliflozin: -0.09 ± 0.79 (ng/mL)2/1000; control: +0.67 ± 0.91 (ng/mL)2/1000; P = 0.096] (Figure 1). In terms of clinical outcomes, dapagliflozin has demonstrated a trend towards decrease in AKI events compared with control (33.3% vs 46.2%; P = 0.513). The change of serum creatinine, adverse events and 28-day mortality showed no differences in both groups.


Initiation of SGLT2 inhibitors in patients with AHF significantly decrease the urinary AKI risk markers TIMP-2 and IGFBP7, that supported protective effect of SGLT2 inhibitor on renal tubular injury.


  • Government Support – Non-U.S.